ClinicalTrials.gg
Not yet recruitingNCT07941336Updated Nov 17, 2026

Acute Effects of Myofascial Release on Squat Jump Performance

An interventional study of Manual myofascial release in Healthy and Athletic Injuries, sponsored by Uskudar University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Uskudar University · Not applicable, Interventional, and Basic science

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Athletic Injuries with a site in Turkey — 10 open to participants now, 12 under way, none of them phase 3. Athletic Injuries · Turkey.

Planned enrollment
4th of 32
60 · median 44
Started
2026
with 10 others
No phase
32 of 53
6 open now
Primary completion
2027-03
later than 7 of 11 live
Registered
53rd of 53
by date
Lead sponsor
4 of 53
Uskudar University

Among the 53 studies in Athletic Injuries with a site in Turkey, this one is the 4th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2026, is one of 32 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 53rd registered.

Athletic Injuries

260 studies on the registry are indexed under Athletic Injuries; 45 are open to participants now.

Browse Athletic Injuries studies →

Open to participants now

10 of the 53 studies in Athletic Injuries with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 22 Athletic Injuries studies recruiting now, 2 (9%) set no upper age limit and 19 (86%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Athletic Injuries with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial will investigate the acute (immediate) effects of a single session of manual myofascial release applied to lower extremity muscles on squat jump height and lower extremity joint kinematics in healthy young adults aged 18-40 years. Sixty volunteers will be randomly assigned to a myofascial release group or a control (rest) group. After a standardized warm-up, all participants will perform three maximal squat jumps. The intervention group will then receive standardized bilateral manual myofascial release to predetermined lower extremity muscle groups, while the control group will rest for an equivalent period. Squat jump testing will then be repeated under identical conditions. Jump height will be measured with the validated smartphone application My Jump 2, and hip, knee and ankle kinematics during the jump will be recorded with a Microsoft Kinect-based markerless motion analysis system.

Read the detailed description

Background: Squat jump (SJ) is a widely used field test of lower extremity explosive strength that isolates concentric force production by eliminating the countermovement. Myofascial release (MFR) is commonly used in physiotherapy and sports settings to improve range of motion and flexibility; however, its acute effects on strength, power and explosive performance vary according to technique, duration and targeted muscle group, and the effects of standardized manual MFR applied to specific lower extremity regions on jump performance and joint kinematics have not been adequately investigated.

Design: Two-arm, parallel-group, randomized controlled trial with a pre-test/post-test design. Participants will be randomly allocated 1:1 to the MFR group or the control group using a computer-generated randomization list. The study will be conducted at the Üsküdar University Physiotherapy and Rehabilitation Application and Research Center (ÜSTFİZYOTEM), Istanbul, Türkiye.

Procedures: After informed consent, demographic and descriptive data (age, sex, height, body mass, dominant lower limb, physical activity habits, injury and surgical history) will be recorded. All participants will receive an explanation of the SJ technique and a standardized warm-up. Baseline testing: participants will perform three maximal vertical squat jumps from a predetermined knee-flexion starting position with hands on hips and without countermovement, with adequate rest between trials. Jump height (cm) will be measured using the My Jump 2 smartphone application from high-speed video (take-off and landing frames). Simultaneously, hip, knee and ankle joint motion during the jump will be recorded with a Microsoft Kinect-based motion analysis system. Intervention: the MFR group will receive standardized bilateral manual myofascial release to four lower extremity muscle groups (gluteal, quadriceps, hamstring and triceps surae) using a sustained cross-hand release technique (90 seconds per muscle group per limb; total application time 12 minutes), with pressure direction, participant position and application region standardized across participants. The control group will rest quietly for an equivalent duration and will receive no manual therapy. Post-testing: immediately after the intervention or rest period, the SJ test will be repeated under identical conditions (same device, technique, position and environment).

Outcomes: The primary outcome is the change in squat jump height (cm, My Jump 2) from pre- to post-intervention. Secondary outcomes are sagittal-plane hip, knee and ankle kinematics during the squat jump obtained from the Kinect-based system: peak flexion (hip, knee) and peak dorsiflexion (ankle) angles in the starting squat position, joint angles at take-off, joint range of motion during propulsion (take-off angle minus starting angle) and, as exploratory variables, peak joint angular extension velocities during the propulsive phase.

Sample size: 60 participants (30 per group). Analysis: Normality will be assessed with the Shapiro-Wilk test, histograms and Q-Q plots. Descriptive data will be presented as mean ± SD or median (IQR) and counts (%). The primary outcome will be analyzed with a two-way mixed-design repeated-measures ANOVA (group × time), with the group × time interaction as the main indicator of the acute effect of MFR; post-hoc pairwise comparisons with correction for multiple comparisons will be performed when appropriate. Non-parametric alternatives will be used if assumptions are violated. Secondary kinematic variables will be analyzed in the same way. Significance will be set at p \< 0.05; effect sizes and 95% confidence intervals will be reported.

03

Conditions studied

  • Healthy
  • Athletic Injuries

Browse trials for

Keywords

  • myofascial release
  • squat jump
  • vertical jump
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-40 years
  • Volunteering to participate and signing the form
  • Ability to perform the squat jump test independently and safely
  • No pain or functional limitation markedly restricting active lower extremity movement or jump performance
  • Ability to understand and follow verbal instructions during the study

Exclusion criteria

Exclusion Criteria:

  • Lower extremity or lumbar surgery within the last 6 months
  • Muscle, tendon, ligament or joint injury of the lower extremity within the last 3 months that may affect jump performance
  • Acute lower extremity or lumbar pain at the time of assessment
  • Neurological, musculoskeletal or cardiovascular disease that may affect jump performance or safe exercise
  • Open wound, active infection, serious dermatological condition or any other in the myofascial release application area
  • Development of pain, dizziness, dyspnea or any symptom preventing safe continuation during testing or application
  • Failure to complete the study protocol or voluntary withdrawal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Myofascial release group

    Standardized warm-up and baseline squat jump testing, followed by a single session of standardized bilateral manual myofascial release applied to predetermined lower extremity muscle groups, followed by post-intervention squat jump testing under identical conditions.

    Other: Manual myofascial release

  • No intervention
    Control (rest) group

    Standardized warm-up and baseline squat jump testing, followed by 12 minutes of quiet seated rest (equivalent to the myofascial release application time), followed by post-test squat jump testing under identical conditions. No manual therapy is applied.

Interventions

  • OtherManual myofascial release

    A single session of manual myofascial release applied bilaterally by a physiotherapist to four lower extremity muscle groups: gluteal muscles (prone), quadriceps (supine), hamstrings (prone) and triceps surae (prone). Technique: sustained cross-hand myofascial release with slow, low-load pressure applied in the direction of tissue restriction until a tissue release is felt, held for 90 seconds per muscle group per limb (4 muscle groups × 2 limbs × 90 s = 12 minutes total), without oil or lubricant. Order of application (gluteal → hamstring → triceps surae → quadriceps), participant position, direction of pressure and duration are standardized for all participants. Applied immediately after baseline squat jump testing; post-testing follows within 2 minutes after the application.

    Also known as: Myofascial release technique; MFR

06

What researchers measure

Primary outcomes

  1. Change in squat jump height

    Vertical squat jump height (cm) measured with the My Jump 2 smartphone application from high-speed video using flight time (take-off and landing frames). Best of three trials (or mean, as predefined in the protocol). Higher values indicate better jump performance.

    Time frame: Baseline (pre-intervention) and immediately after the intervention/rest period (approximately 15-20 minutes after baseline, same session)

Secondary outcomes

  1. Change in peak hip flexion angle in the starting squat position

    Sagittal-plane peak hip flexion angle (degrees) in the predetermined starting squat position immediately before propulsion, recorded with a Microsoft Kinect-based markerless motion analysis system; mean of three trials.

    Time frame: Baseline and immediately after the intervention/rest period (same session)

  2. Change in peak knee flexion angle in the starting squat position

    Sagittal-plane peak knee flexion angle (degrees) in the starting squat position, Kinect-based system; mean of three trials.

    Time frame: Baseline and immediately after the intervention/rest period (same session)

  3. Change in sagittal-plane ankle, hip and knee kinematics during the squat jump

    Composite set of sagittal-plane kinematic variables recorded with a Microsoft Kinect-based markerless motion analysis system (mean of three trials): (a) peak ankle dorsiflexion angle in the starting squat position (degrees); (b) hip, knee and ankle joint angles at the instant of take-off, defined as the last frame of foot contact (degrees); (c) hip, knee and ankle range of motion during the propulsive phase, calculated as take-off angle minus starting-position angle (degrees); and (d) peak hip, knee and ankle angular extension velocities during the propulsive phase (degrees/second), reported as exploratory given the 30 Hz sampling rate.

    Time frame: Baseline and immediately after the intervention/rest period (same session)

07

Study locations

1 site
08

References and documents

Publications

  • Gencoglu C, Ulupinar S, Ozbay S, Turan M, Savas BC, Asan S, Ince I. Validity and reliability of "My Jump app" to assess vertical jump performance: a meta-analytic review. Sci Rep. 2023 Nov 17;13(1):20137. doi: 10.1038/s41598-023-46935-x. PubMed 37978338 ↗
  • Vieira A, Ribeiro GL, Macedo V, de Araujo Rocha Junior V, Baptista RS, Goncalves C, Cunha R, Tufano J. Evidence of validity and reliability of Jumpo 2 and MyJump 2 for estimating vertical jump variables. PeerJ. 2023 Jan 25;11:e14558. doi: 10.7717/peerj.14558. eCollection 2023. PubMed 36718456 ↗
  • Franca MED, Amorim MDS, Sinhorim L, Santos GM, do Nascimento IB. Myofascial release strategies and technique recommendations for athletic performance: A systematic review. J Bodyw Mov Ther. 2023 Oct;36:30-37. doi: 10.1016/j.jbmt.2023.04.085. Epub 2023 May 10. PubMed 37949575 ↗

Individual participant data

Plan to share: Undecided — De-identified individual participant data may be made available from the principal investigator upon reasonable request after publication of the main results.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 2 months later.

Of 121 non-industry interventional studies with no phase under Athletic Injuries, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 14. This study's planned 2 months is below that.

Counting every sponsor, half of 123 studies reached it within 5 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941336
Lead sponsor
Uskudar University
Responsible party
Doç.Dr.Ömer Şevgin (Üsküdar University, Uskudar University) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Ömer Şevgin
Contact
omer.sevgin@uskudar.edu.tr
+905069787535
Parsa KEİHANİ
study chair · Üsküdar University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion